- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Repligen Stock Position Raised by Congress Asset Management Co.
Biotechnology company sees significant institutional investment increase in Q4 2025.
Mar. 24, 2026 at 8:38am
Got story updates? Submit your updates here. ›
Congress Asset Management Co. grew its position in shares of Repligen Corporation (NASDAQ:RGEN) by 241.4% in the 4th quarter, according to the company's recent SEC filing. The fund now owns 746,306 shares of the biotechnology company's stock, representing approximately 1.33% of Repligen's total shares outstanding.
Why it matters
The substantial increase in institutional ownership of Repligen stock suggests growing confidence in the company's long-term prospects among major investors. As a leading provider of critical bioproduction technologies, Repligen's performance is seen as a bellwether for the broader biotechnology industry.
The details
Congress Asset Management Co. acquired an additional 527,714 shares of Repligen in the fourth quarter, bringing its total position to 746,306 shares. This represents a significant vote of confidence in the company's growth potential, as the fund now owns over 1% of Repligen's outstanding stock. The biotechnology company specializes in technologies that support the development and production of biopharmaceuticals, including chromatography resins, filtration membranes, and single-use systems.
- Congress Asset Management Co. filed its Q4 2025 holdings report with the SEC on March 24, 2026.
The players
Congress Asset Management Co.
An institutional investment management firm that provides asset management services to clients, including pension funds, endowments, and high-net-worth individuals.
Repligen Corporation
A life sciences company that develops and manufactures high-value consumable products for bioprocessing applications, including chromatography resins, filtration membranes, and single-use technologies.
The takeaway
The significant increase in institutional ownership of Repligen stock by a major investment firm like Congress Asset Management Co. suggests that the biotechnology company's products and technologies are seen as increasingly valuable in the rapidly growing biopharmaceutical industry.
